Peptide Manufacturing Facility
We operate a manufacturing facility in Shenzhen, China, and a marketing company in Hong Kong, China. With a team of more than 50 chemists and experienced professionals, we are committed to delivering reliable peptide products and professional customer support. Our advanced chemical technologies and state-of-the-art equipment enable us to provide outstanding product quality while maintaining competitive manufacturing costs.
We operate a manufacturing facility in Shenzhen, China, and a marketing company in Hong Kong, China. With a team of more than 50 chemists and experienced professionals, we are committed to delivering reliable peptide products and professional customer support. Our advanced chemical technologies and state-of-the-art equipment enable us to provide outstanding product quality while maintaining competitive manufacturing costs.
The Largest Peptide Production Manufacturer
As sales continue to increase, we will become one of the world’s leading cGMP-certified peptide research manufacturers. Our quality system is adaptable to companies or laboratories of any size, including the largest commercial projects.
DYAK can serve its partners from the project initiation/discovery phase (including R&D) all the way to commercial production, supporting optimized process development. We utilize solid-phase, liquid-phase, and mixed peptide chemistry methods to produce the peptide products required throughout the project lifecycle.
Setting new standards for peptide manufacturing and services
Peptide Production Has Been Developed
For years, the pharmaceutical industry has largely avoided developing peptide drugs. Small molecule drugs have always been more popular than peptides. However, small molecule drugs lack the advantages of peptides, such as high selectivity and rapid onset of action. Furthermore, peptides are eliminated from the body very quickly due to their short half-life.
Roche’s Fuzeon has revolutionized peptide development. The metric-tonn-scale supply chain required to produce this peptide active pharmaceutical ingredient has completely transformed peptide manufacturing.
The decreasing cost of key amino acids and other raw materials from Fmoc has spurred peptide development projects from numerous biotechnology and pharmaceutical companies worldwide. In addition, improvements in production methods and delivery systems have significantly increased the volume of peptides that are either already approved as drugs or currently undergoing clinical evaluation.